Signadori Bio: Seed+Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stageOct 4, 2026RoundOSSignadori BioCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechFranceHealthtechEuropeSeed